Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immune Pharmaceuticals announced that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals, a subsidiary of Endo International.
Subscribe to our email newsletter
As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents. Endo will pay undisclosed milestones to Immune if Endo receives a back pain indication for a lidocaine-based product, as per the original 2003 Licensing Agreement.
Immune will re-gain full exclusive rights to develop, commercialize and license LidoPain, a high-dose lidocaine patch for the treatment of acute pain. LidoPain is currently in Phase II clinical development.
Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.
The Company’s lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition.
Immune’s pipeline also includes NanomAbs, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet, a topical Neuropathic Pain drug candidate ready for Phase III.